您当前所在的位置:首页 > 产品中心 > 产品信息
Gadoteridol_分子结构_CAS_120066-54-8)
点击图片或这里关闭

Gadoteridol

产品号 DB00597 公司名称 DrugBank
CAS号 120066-54-8 公司网站 http://www.ualberta.ca/
分子式 C17H29GdN4O7 电 话 (780) 492-3111
分子量 558.68476 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 479

产品价格信息

请登录

产品别名

标题
Gadoteridol
IUPAC标准名
gadolinium(3+) ion 2-[4,7-bis(carboxylatomethyl)-10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetate
IUPAC传统名
gadolinium(3+) 2-[4,7-bis(carboxylatomethyl)-10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetate
商标名
Prohance Multipack
ProHance

产品登记号

CAS号 120066-54-8
PubChem SID 46505738
PubChem CID 60714

产品性质

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies. n MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts.
Indication Gadoteridol is an MRI contrast agent used for contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies.
Affected Organisms
Humans and other mammals
Half Life Distribution 12 minutes (mean), elimination 100 minutes (mean).
Elimination Gadoteridol is eliminated in the urine with 94.4 ± 4.8% (mean ± SD) of the dose excreted within 24 hours post-injection.
Distribution * 204 ± 58 mL/kg
Clearance * 1.50+/- 0.35 mL/ min/kg
* renal cl=1.41 +/- 0.33 mL/ min/kg

参考文献